Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials (Q45414505)
Jump to navigation
Jump to search
scientific article published in May 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials |
scientific article published in May 2012 |
Statements
1 reference
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials (English)
1 reference
Beatriz Grinsztejn
1 reference
Bonaventura Clotet
1 reference
Michael Saag
1 reference
Jean-Michel Molina
1 reference
Katia Boven
1 reference
Simon Vanveggel
1 reference
Pedro Cahn
1 reference
Calvin J Cohen
1 reference
Jan Fourie
1 reference
Hao Wu
1 reference
Margaret A Johnson
1 reference
Khuanchai Supparatpinyo
1 reference
Herta Crauwels
1 reference
Eric Lefebvre
1 reference
Laurence T Rimsky
1 reference
Peter Williams
1 reference
ECHO Study Group
1 reference
THRIVE Study Group
1 reference
1 May 2012
1 reference
1 reference
Identifiers
1 reference